About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

RECRUITINGNCT05022238

Hotspots, Households and Hospitals: Enhanced Drug-resistant Tuberculosis Case Finding in Namibia

Poor case management, pharmacokinetic variability and on-going transmission have fostered the drug-resistant tuberculosis (DR-TB) epidemic leading to a global estimated number of \>500,000 new multidr...

Lead sponsor: University of Namibia•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Contacts

Mareli Claassens, PhD

CONTACT

264814482082 mclaassens@unam.na

Sponsors

Lead Sponsor

University of Namibia

Collaborators

UK Medical Research Council (MRC)
European and Developing Countries Clinical Trials Partnership (EDCTP)
Research Center Borstel
Imperial College London
University of Stellenbosch
National Taiwan University
Namibian National Tuberculosis and Leprosy Programme (NTLP)
UK Foreign, Commonwealth & Development Office (FCDO)

Age

All ages

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•All cases diagnosed with drug-resistant TB in Namibia, in three regions of Khomas, Otjozondjupa and Ohangwena will be included for the first outcome. For the second outcome, all household members of DR-TB cases will be included; all hospital visitors to DR-TB cases will be included and community members at transmission hotspots will be included.

Exclusion Criteria

•Anyone who does not give consent to participate.

Related studies

RECRUITINGPhase 2

Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TB

NCT02354014 · Tuberculosis, Multidrug-Resistant

RECRUITINGPhase 3

A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients

NCT05824871 · Rifampin-Resistant Pulmonary Tuberculosis, Tuberculosis, Multidrug-Resistant (MDR-TB)

Active Not RecruitingPhase 2

Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB

NCT03828201 · Tuberculosis, Multidrug-Resistant

Active Not Recruiting

Strengthening Evidence on Optimal Multidrug-resistant Tuberculosis Treatment Regimens

NCT05871489 · Tuberculosis, Multidrug-Resistant, HIV

COMPLETEDPhase 2

Treatment Shortening of MDR-TB Using Existing and New Drugs

NCT02619994 · Tuberculosis, Multidrug-Resistant

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 24, 2024Terms

Trial snapshot

StatusRECRUITING

Phase—

Enrollment2,100

Start dateAug 2022

Last updatedOct 24, 2024

Condition

Tuberculosis, Multidrug-Resistant

Locations shown

University of Namibia

Windhoek

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 24, 2024Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions